Search clinical trials for: travoprost 0.003%

Total 382 results

Summa Health System

Completed

The Effects of Xalatan, Travatan and Lumigan on Skin Pigmentation Near the Eye

Glaucoma | Application Site Pigmentation Changes

United States
Innovative Medical

Completed

Diurnal Curves With Bimatoprost 0.03% Versus Travoprost 0.004%

Glaucoma

United States
Allergan

Completed

Safety and Efficacy Study of Bimatoprost, Latanoprost, and Travoprost in Patients With Elevated Intraocular Pressure (IOP) and Open-angle Glaucoma (OAG)

Ocular Hypertension | Open-Angle Glaucoma

United States
Alcon Research

Completed

Travoprost 3-Month Safety and Efficacy Study

Ocular Hypertension | Open-Angle Glaucoma
Allergan

Completed

Evaluation of Hyperemia With the Use of Ocular Prostaglandin Analogues

Ocular Hypertension | Open Angle Glaucoma

United States
Alcon Research

Completed

A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Chronic Angle-Closure Glaucoma

Ocular Hypertension | Glaucoma, Angle-Closure

United States, Australia
University Hospital, Basel, Switzerland

Completed

Influence of Prostaglandins on Ocular Blood Flow in Glaucoma Patients

Open-Angle Glaucoma

Switzerland
Aerie Pharmaceuticals

Completed

AR-12286 Fixed Dose Combination to Lower Elevated Intraocular Pressure

Ocular Hypertension | Glaucoma

United States
Alcon Research

Completed

Divided Dose of TRAVATAN®

Ocular Hypertension | Open-angle Glaucoma
Semmelweis University

Completed

Continuous Intraocular Pressure (IOP) Measurement and Ability to Detect Treatment Effect

Ocular Hypertension | Glaucoma

Hungary
Allergan

Completed

Bimatoprost 0.03% Versus Travoprost 0.004% in Patients Currently on Latanoprost 0.005%

Ocular Hypertension | Glaucoma

United States
Alcon Research

Completed

Travoprost Five Day Posology Study

Ocular Hypertension | Open-angle Glaucoma (OAG)

United States
Kasr El Aini Hospital

Completed

Comparison Between Latanoprost , Travoprost and Tafluprost in Reducing IOP Fluctuation in POAG Patients

Primary Open Angle Glaucoma

Egypt
Alcon Research

Completed

Effects of Travatan Z and Xalatan on Ocular Surface Health

Ocular Hypertension | Glaucoma
Alcon Research

Terminated

Azopt (Brinzolamide 1.0%) Plus Travatan (Travoprost 0.004%) in Treating Patients With Chronic Angle-Closure Glaucoma (CACG)

Intraocular Pressure

United States
Alcon Research

Completed

Efficacy Study of Travoprost APS Versus TRAVATAN

Ocular Hypertension | Open Angle Glaucoma
Alcon Research

Completed

Phase III Safety and Efficacy Study to Evaluate a Glaucoma Therapy in Open-Angle Glaucoma or Ocular Hypertension Patients

Ocular Hypertension | Open-angle Glaucoma
Alcon Research

Completed

Efficacy of Changing to TRAVATAN® From Prior Therapy

Ocular Hypertension | Open-Angle Glaucoma
BioMarin Pharmaceutical

Completed

Dose-Finding Study to Evaluate the Safety, Efficacy, & Tolerability of Multiple Doses of rAvPAL-PEG in Subjects With PKU

Phenylketonuria

United States
Alcon Research

Completed

Safety and Intraocular Pressure (IOP) Lowering Efficacy of Low Dose Travoprost

Ocular Hypertension | Open-angle Glaucoma

United States
Alcon Research

Completed

Travatan Z in Ocular Surface Health in Patients With Open-Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Open-angle Glaucoma
Alcon Research

Completed

Examination of Ocular Surface Effects With Administration of Travatan Z and XALATAN

Ocular Hypertension | Open-angle Glaucoma
Alcon Research

Completed

A Single Dose Comfort Comparison of Travatan Z in One Eye Versus Xalatan in the Opposite Eye in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Open-Angle Glaucoma
Alcon Research

Completed

Phase III Clinical Trial of TRAVATAN Z in Ocular Surface Health

Ocular Hypertension | Open-angle Glaucoma
Alcon Research

Completed

Pharmacokinetic and Safety Study of Travoprost 0.004% in Pediatric Glaucoma Patients

Ocular Hypertension | Glaucoma
Alcon Research

Completed

A 12-Month Study to Evaluate the Efficacy and Safety of Once-Daily Instillation of Combination Glaucoma Therapy in Patients With Open-Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma, Open-angle

Belgium
Alcon Research

Completed

Efficacy of Changing to TRAVATAN® From Prior Therapy

Ocular Hypertension | Open-angle Glaucoma
Allergan

Completed

Ocular Surface Tolerability Study of Prostaglandin Analogues in Patients With Open-Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma, Open-Angle

Canada, United States
Laboratorios Sophia S.A de C.V.

Completed

Safety and Tolerability of the Ophthalmic Solution PRO-179 Compared With Travatan® (PRO-179/I)

Glaucoma

Mexico
Innovative Medical

Completed

Bimatoprost Monotherapy vs. Dual Therapy With Travoprost and Timolol in Patients With Glaucoma and Ocular Hypertension

Glaucoma

United States
Alcon Research

Completed

A 6-Week Safety and Efficacy Study of Travatan Compared to Xalcom in Subjects With Open-Angle Glaucoma(OAG) or Ocular Hypertension(OHT)

Ocular Hypertension | Glaucoma, Open-Angle

United States
Alcon Research

Completed

Investigation of Intraocular Pressure (IOP) Reduction Efficacy of Travoprost Ophthalmic Solution in Patients With Normal Tension Glaucoma

Ocular Hypertension | Normal Tension Glaucoma

Japan
Alcon Research

Terminated

Study of TRAVATAN in Subjects With Iris Pigmentation Changes

Ocular Hypertension | Open-Angle Glaucoma
Alcon Research

Withdrawn

Three Month Safety and Efficacy Study of TRAVATAN® Versus Travoprost Ophthalmic Solution, 0.004%

Ocular Hypertension | Open Angle Glaucoma
Lee's Pharmaceutical Limited

Suspended

Antiplatelet Thrombolysin (Anfibatide) Phase 1 Clinical Trial in Healthy Volunteers

Antiplatelet Drug

China
Assiut University

Unknown

Effect Of Topical Prostaglandin F2α Analogs,Fractional CO2 Laser, Excimer Laser Or Their Combination In Treatment Of Vitiligo

Vitiligo | Excimer Laser | Fractional CO2 Laser
United States Air Force
Alcon Research

Completed

Dry Eye and Irritation Comparison of Latanoprost With the Preservative Versus Travoprost Without Preservative

Ocular Hypertension | Open-Angle Glaucoma | Ocular Dryness | Ocular Irritation

United States
Eisai Inc.

Completed

Paired-Comparison Study Evaluating the Efficacy and Safety of E6201 Versus Vehicle for the Treatment of Plaque-Type Psoriasis

Chronic Plaque Psoriasis

United States
Alcon Research

Completed

Travoprost New Formulations in Patients With Open-Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Open-angle Glaucoma
Alcon Research

Completed

Travoprost 0.004%/Timolol 0.5% Versus Latanoprost 0.005%/Timolol in Chinese Patients With Open-Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Open-angle Glaucoma

China
Alcon Research

Terminated

A Multicenter Study of the Pigmentation in the Trabecular Meshwork After Two Years of Treatment With TRAVATAN 0.004% Ophthalmic Solution

Open-angle Glaucoma
Alcon Research

Completed

Phase II Safety and Efficacy Study to Evaluate a Glaucoma Therapy in Open-angle Glaucoma or Ocular Hypertension Patients

Ocular Hypertension | Open-angle Glaucoma
Alcon Research

Completed

A Phase III Study of Travoprost/Timolol Combination in Patients With Open-Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Open-Angle Glaucoma
Alcon Research

Completed

Safety and Efficacy of Travoprost/Timolol BAC-free

Ocular Hypertension | Open-Angle Glaucoma

Japan
Alcon Research

Completed

Efficacy and Safety of Travoprost 0.004% Versus Tafluprost 0.0015% in Patients With Primary Open-angle Glaucoma or Ocular Hypertension

Glaucoma
Alcon Research

Completed

An Efficacy and Tolerability Study of TRAVATAN® Versus LUMIGAN®

Ocular Hypertension | Glaucoma
Aerie Pharmaceuticals

Completed

Ocular Hypotensive Efficacy of AR-102

Glaucoma

United States
Aerie Pharmaceuticals

Completed

A Study Assessing PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components for 28 Days

Ocular Hypertension | Open Angle Glaucoma

United States
Alcon Research

Completed

Assessment of Intraocular Pressure (IOP) Control in Subjects With Open-Angle Glaucoma or Ocular Hypertension Treated With Travoprost 0.004% (TRAVATAN® Z) or Bimatoprost 0.01% (LUMIGAN®)

Ocular Hypertension | Glaucoma | Open-Angle Glaucoma
Alcon Research

Completed

A Phase IIIb Study of DuoTrav to Treat Glaucoma or Ocular Hypertension

Ocular Hypertension | Open-angle Glaucoma

United States

3

Subscribe